The Vacaville, Calif.-based company did not break out figures for its wholly owned biomarker-company subsidiary.
LSB attributed the severe decline to the loss of $800,000 in revenues generated during the third quarter of 2003 by its Germantown, Md.-based contract proteomics business, which it closed last November ( see ProteoMonitor, GenomeWeb News' sister publication ).
The company spent $2.3 million on R&D in the period, down slightly from $2.7 million year over year.
Consequently, net losses for the third quarter narrowed to $4.2 million, or $.13 per share, from $4.3 million, or $.17 per share, in 2003.
The results do not include one full quarter of activity related to Predictive Diagnostics' agreement with PerkinElmer, which the companies announced in late September. Under the agreement, PerkinElmer will offer the Predictive Diagnostics' Biomarker Amplification Filter technology to complement its own prOTOF 2000 MALDI O-TOF mass spectrometer.
LSB ended the quarter with $3.9 million in cash and marketable securities.